CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| RTOG-BR-0118 | RTOG | A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC# 66847) Versus Conventional Radiation Therapy For Multiple Brain Metastases | Adult CIRB - Late Phase Emphasis | Completed |
| EA8141 | ECOG-ACRIN | A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma | Adult CIRB - Late Phase Emphasis | Completed |
| EA7211 | ECOG-ACRIN | A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2) | Adult CIRB - Late Phase Emphasis | Available to Open |
| EAA173 | ECOG-ACRIN | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | Adult CIRB - Late Phase Emphasis | Available to Open |
| A031803 | Alliance | Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
| E1301 | ECOG | A Phase III Randomized Study of Adjuvant Biologic Therapy in Patients With States III/IV Head and Neck Squamous Cell Carcinoma | Adult CIRB - Late Phase Emphasis | Completed |
| CALGB-10201 | CALGB | A Phase III Study of Daunorubicin and Cytarabine +\- G3139 (GenasenseTM; Oblimersen Sodium; NSC #683428; IND #58842); A BCL2 Antisense Oligodeoxynucleotide; in Previously Untreated Patients with Acute Myeloid Leukemia (AML) > 60 Years | Adult CIRB - Late Phase Emphasis | Completed |
| S1905 | SWOG | A Phase I/II Study of AKR1C3-Activated Prodrug OBI‐3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL) | Adult CIRB - Late Phase Emphasis | Available to Open |
| RTOG-0521 | RTOG | A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT followed by Chemotherapy with Docetaxel and Prednisone for Localized; High-Risk Prostate Cancer | Adult CIRB - Late Phase Emphasis | Completed |
| NRG-GU009 | NRG | Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT) | Adult CIRB - Late Phase Emphasis | Available to Open |